The new antidepressant zimeldine in general practice. A surveillance study of 15,000 patients.
The safety and efficacy of zimeldine--the 5-HT reuptake blocker--was investigated in a 3-week open surveillance study of 15,000 out-patients with depressive illness. In general, a single daily dose of 200 mg of zimeldine was given to adults for a minimum of 3 weeks. Patients of 65 years or over received 100 mg. The drug was well tolerated and troublesome side-effects occurred in only a small percentage of patients. No previously unencountered side-effects or new pattern of side-effects emerged from this study. The general impression of the efficacy of zimeldine confirmed previous findings (i.e. that zimeldine is an effective antidepressant).
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D005194:Family Practice; D005260:Female; D005860:Germany, West; D006801:Humans; D008297:Male; D008875:Middle Aged; D015031:Zimeldine / Q000009:adverse effects / Q000627:therapeutic use*
D015031:Zimeldine